Back to Journals » OncoTargets and Therapy » Volume 11

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab

Authors Bylicki O, Paleiron N, Rousseau-Bussac G, Chouaïd C

Received 27 April 2018

Accepted for publication 19 June 2018

Published 16 July 2018 Volume 2018:11 Pages 4051—4064

DOI https://doi.org/10.2147/OTT.S154606

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Takuya Aoki


Olivier Bylicki,1 Nicolas Paleiron,2 Gaëlle Rousseau-Bussac,3 Christos Chouaïd3

1Pneumology Department, Hôpital d’Instruction des Armées Percy, Paris, 2Respiratory Department, Hôpital d’Instruction des Armées Saint-Anne, Toulon, 3Pneumology Department, CHI Créteil, Paris, France

Abstract:
The advent of immune-checkpoint inhibitors during the past decade represents a major advancement in the treatment of non-small cell lung cancer (NSCLC) with personalized treatment. Platinum-based chemotherapy has reached its efficacy threshold, with its use remaining limited by its toxicity. For NSCLC, inhibitors of the PD1 protein and its ligand PDL1 show promising clinical activity and induce durable responses in patients with advanced disease. The US Food and Drug Administration has approved pembrolizumab for treatment-naïve metastatic NSCLC with ≥50% of tumor cells expressing PDL1 and for metastatic NSCLC with ≥1% PDL1 expression after progression following first-line platinum-based doublet chemotherapy. In 2017, it also authorized the first-line combination of pembrolizumab and carboplatin–pemetrexed chemotherapy without selection based on PDL1 expression, but European health authorities are still waiting for the results of a Phase III trial. In this review, the clinical results of published and ongoing studies evaluating pembrolizumab for advanced NSCLC are analyzed and the potential role of PDL1 as a factor predictive of overall responses addressed.

Keywords: pembrolizumab, immune-checkpoint inhibitor, NSCLC, PDL1

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]